ER+/HER2− Breast Cancer Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

ER+/HER2− Breast Cancer Epidemiology Forecast Report Coverage

Expert Market Research's “ER+/HER2− Breast Cancer Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of ER+/HER2− breast cancer. It projects the future incidence and prevalence rates of ER+/HER2− breast cancer cases across various populations. The study covers age, gender, and type as major determinants of the ER+/HER2− breast cancer population. The report highlights patterns in the prevalence of ER+/HER2− breast cancer over time and projects future trends based on multiple variables.

ER+/HER2− Breast Cancer Understanding: Disease Overview

ER-positive HER2-negative breast cancer is a common subtype of breast cancer characterized by the presence of estrogen receptors (ER-positive) and the absence of overexpression of human epidermal growth factor receptor 2 (HER2-negative). It occurs when breast cells grow uncontrollably under the influence of estrogen signaling. This subtype typically develops in hormone-sensitive tissues and is often associated with slower progression compared to HER2-positive disease. It includes early-stage and metastatic forms and may be further classified based on tumor grade, stage, and molecular profiling such as luminal A and luminal B subtypes.

ER+/HER2− Breast Cancer Epidemiology Perspective

The ER+/HER2− breast cancer epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the ER+/HER2− breast cancer epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for ER+/HER2− breast cancer and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Oncology Nurse Advisor, hormone receptor–positive/human epidermal growth factor receptor 2–negative breast cancer accounts for about 69% of cases in the United States, making it the most prevalent subtype, with comparatively lower proportions observed for other molecular subtypes.
• According to Jenny Gilchrist (2024), approximately 65% of diagnosed breast cancers are luminal (estrogen receptor and/or progesterone receptor positive, HER2-negative), with a median diagnosis age of 61 years, indicating higher occurrence in older populations compared to other subtypes.
• According to Pegah Farrokhi et al. (2026), incidence is about 15% lower in Black women than White women; however, mortality is 19% higher among Black women, driven by disparities in tumor stage at diagnosis, healthcare access, and socioeconomic factors.
• As per Pegah Farrokhi et al. (2026), gender distribution is overwhelmingly female, but racial disparities persist, with Black patients more frequently diagnosed at younger ages and with more aggressive disease characteristics compared to White patients.
• According to Hong Lv et al., HER2-low tumors constitute approximately 60–67% of HER2-negative breast cancers globally, highlighting a substantial epidemiological subgroup within ER-positive/HER2-negative disease, although region-specific data, particularly from China, remain limited.

Read more about this report - Request a Free Sample

Country-wise ER+/HER2− Breast Cancer Epidemiology

The ER+/HER2− breast cancer epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Across the regions, the epidemiology of estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer reflects broader breast cancer incidence trends with notable regional variation. According to Cancer Network, in the year 2024, approximately 2,001,140 new cancer cases and 611,720 cancer deaths are projected in the United States with declining mortality attributed to improved detection and treatment. In India, as per Cancer Rounds, nearly 60-70% of breast cancer cases are hormone receptor–positive, indicating a substantial ER+ burden, a pattern similarly observed across developed markets.

ER+/HER2− Breast Cancer: Treatment Overview

The treatment of ER-positive HER2-negative breast cancer primarily focuses on hormone (endocrine) therapy, which either blocks estrogen activity or reduces its production. Common approaches include selective estrogen receptor modulators, aromatase inhibitors, and estrogen receptor degraders. Depending on the disease stage and risk factors, treatment may also involve surgery, radiation therapy, and chemotherapy. In advanced or metastatic cases, targeted therapies such as cyclin-dependent kinase 4/6 inhibitors, phosphatidylinositol 3-kinase inhibitors, and mechanistic target of rapamycin inhibitors are often combined with endocrine therapy to improve outcomes and delay disease progression.

Key Questions Answered

• What are the key findings of ER+/HER2− breast cancer epidemiology in the 8 major markets?
• What will be the total number of patients with ER+/HER2− breast cancer across the 8 major markets during the forecast period?
• What was the country-wise ER+/HER2− breast cancer epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of ER+/HER2− breast cancer patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of ER+/HER2− breast cancer during the forecast period of 2026-2035?
• What are the currently available treatments for ER+/HER2− breast cancer?
• What are the disease risks, signs, symptoms, and unmet needs of ER+/HER2− breast cancer?

Scope of the ER+/HER2− Breast Cancer Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of ER+/HER2− breast cancer based on several factors.
• ER+/HER2− Breast Cancer Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The ER+/HER2− breast cancer report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

HER2-Negative Breast Cancer Pipeline Analysis Report

HER2 Positive Breast Cancer Pipeline Analysis Report

HER2-Positive Early Breast Cancer Epidemiology Forecast